High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
| Autor: | Wang WS; Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C., Tzeng CH, Chiou TJ, Liu JH, Fan S, Chen PM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Zhonghua yi xue za zhi = Chinese medical journal; Free China ed [Zhonghua Yi Xue Za Zhi (Taipei)] 1996 Feb; Vol. 57 (2), pp. 100-5. |
| Abstrakt: | Background: High-dose cytarabine (ara-C) alone or in combination with mitoxantrone each has shown to be active in therapeutic trials of refractory non-Hodgkin's lymphoma (NHL). In this study, we administered these two drugs to 14 patients with advanced and refractory NHL. Methods: Ara-C was administered at a dosage of 3 gm/sqm for 2-hour intravenous infusion every 12 hours from day 1 to day 4 (8 doses), and mitoxantrone was given at a dosage of 6 mg/sqm/day for 1-hour intravenous infusion from day 1 to day 5. The clinical efficacy and toxicity were assessed by WH0 criteria. Results: Four patients (28%) attained complete remission (CR) and 2 had partial remission (PR). Of the 4 CR patients, the remission lasted 5 months in one patient and 4 months in another. The remaining 2 patients had CR of only 1.3 months. Myelosup-pression with subsequent infection was the major toxicity of this regimen. Severe neutropenia (<1,000/uL) lasted for an average of 20 days, and thrombocytopenia (<50,000/uL) 24 days. Nonmyeloid toxicities included 100% alopecia, 93% stomatitis, 43% hepatotoxicity, 36% dermatitis, 28% CNS toxicity and 7% chemical conjunctivitis. Conclusions: A proportion of refractory NHL patients will respond to high-dose ara-C + mitoxantrone, despite that severe myelosuppression is frequently encountered. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|